Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

Wanwisa Dejnirattisai; Robert H Shaw; Piyada Supasa; Chang Liu; Arabella SV Stuart; Andrew J Pollard; Xinxue Liu; Teresa Lambe; Derrick Crook; Dave I Stuart; Juthathip Mongkolsapaya; Jonathan S Nguyen-Van-Tam; Matthew D Snape; Gavin R Screaton; the Com-COV2 study group

doi:10.1101/2021.12.10.21267534

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

Wanwisa Dejnirattisai, Robert H Shaw, Piyada Supasa, Chang Liu, Arabella SV Stuart, Andrew J Pollard, Xinxue Liu, Teresa Lambe, Derrick Crook, Dave I Stuart, Juthathip Mongkolsapaya, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Gavin R Screaton, the Com-COV2 study group

doi: https://doi.org/10.1101/2021.12.10.21267534

Wanwisa Dejnirattisai

1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Robert H Shaw

3Oxford Vaccine Group, Department of Paediatrics, University of Oxford

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Piyada Supasa

1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Chang Liu

1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Arabella SV Stuart

3Oxford Vaccine Group, Department of Paediatrics, University of Oxford

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andrew J Pollard

3Oxford Vaccine Group, Department of Paediatrics, University of Oxford

4NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, University of Oxford, Oxford, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Xinxue Liu

3Oxford Vaccine Group, Department of Paediatrics, University of Oxford

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Teresa Lambe

2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

3Oxford Vaccine Group, Department of Paediatrics, University of Oxford

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Derrick Crook

4NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, University of Oxford, Oxford, UK

5Nuffield Department of Medicine, University of Oxford, Oxford, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Dave I Stuart

1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

6Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK

7Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK

8Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Juthathip Mongkolsapaya

1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

9Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jonathan S Nguyen-Van-Tam

10Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthew D Snape

3Oxford Vaccine Group, Department of Paediatrics, University of Oxford

4NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, University of Oxford, Oxford, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: matthew.snape{at}paediatrics.ox.ac.uk

Gavin R Screaton

1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK

2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

Supplementary appendix[supplements/267534_file03.docx]

View the discussion thread.

PreviousNext

Posted December 11, 2021.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

Message Subject (Your Name) has forwarded a page to you from medRxiv

Message Body (Your Name) thought you would like to see this page from the medRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

medRxiv 2021.12.10.21267534; doi: https://doi.org/10.1101/2021.12.10.21267534

Share This Article:

Citation Tools

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

medRxiv 2021.12.10.21267534; doi: https://doi.org/10.1101/2021.12.10.21267534

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Tweet Widget
Facebook Like
Google Plus One

Subject Area

Infectious Diseases (except HIV/AIDS)

Subject Areas

All Articles

Addiction Medicine (427)
Allergy and Immunology (753)
Anesthesia (220)
Cardiovascular Medicine (3281)
Dentistry and Oral Medicine (362)
Dermatology (274)
Emergency Medicine (478)
Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
Epidemiology (13340)
Forensic Medicine (19)
Gastroenterology (897)
Genetic and Genomic Medicine (5130)
Geriatric Medicine (479)
Health Economics (781)
Health Informatics (3253)
Health Policy (1138)
Health Systems and Quality Improvement (1189)
Hematology (427)
HIV/AIDS (1014)
Infectious Diseases (except HIV/AIDS) (14613)
Intensive Care and Critical Care Medicine (910)
Medical Education (475)
Medical Ethics (126)
Nephrology (522)
Neurology (4901)
Nursing (261)
Nutrition (725)
Obstetrics and Gynecology (880)
Occupational and Environmental Health (795)
Oncology (2516)
Ophthalmology (722)
Orthopedics (280)
Otolaryngology (346)
Pain Medicine (323)
Palliative Medicine (90)
Pathology (540)
Pediatrics (1298)
Pharmacology and Therapeutics (548)
Primary Care Research (554)
Psychiatry and Clinical Psychology (4193)
Public and Global Health (7482)
Radiology and Imaging (1702)
Rehabilitation Medicine and Physical Therapy (1010)
Respiratory Medicine (979)
Rheumatology (478)
Sexual and Reproductive Health (495)
Sports Medicine (424)
Surgery (546)
Toxicology (71)
Transplantation (235)
Urology (203)